Welcome to drugdiscoveryanddevelopment.co.uk
Click to listen highlighted text!
Welcome to drugdiscoveryanddevelopment.co.uk
Subscribe to newsletter
Facebook
Linkedin
X
Youtube
Linkedin
Twitter
Youtube
Tue 15 September 2026
A Pharma Press Global company
Subscribe to DDD newsletter
Search
Drug Discovery and Development
Drug Discovery
Investigational New Drug application
Phase 1-2 trials
Phase 3 trials
Approvals
Finance
Conferences
Journal
Drug Discovery
Investigational New Drug application
Phase 1-2 trials
Phase 3 trials
Approvals
Novartis remibrutinib significantly reduces relapse rates and shows favourable safety profile in phase 3 RMS trials
9 September 2026
GSK to advance mRNA seasonal flu vaccine candidate to phase 3 following positive phase 2 data
9 September 2026
New phase 3b data on Eli Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults...
8 September 2026
Acoramidis demonstrates reversal of cardiac structural disease progression and functional decline and significantly increases days alive and free from hospitalisation in ATTR-CM
8 September 2026
Tezspire demonstrates positive phase 3 results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
8 September 2026
Products
CDMO
CRO
Tags
Clinicaltrials
Tag:
clinicaltrials
Phase 1-2 trials
Ractigen Therapeutics announces completion of enrolment and first dosing in phase 2 clinical trial of RAG-17 for SOD1-ALS
Editor
-
10 August 2026
0
Phase 1-2 trials
Clinical trial network to advance development of ATV-1601 for hereditary haemorrhagic telangiectasia
Editor
-
30 July 2026
0
Phase 3 trials
Jazz Pharmaceuticals provides update on Zepzelca (lurbinectedin) phase 3 trial in second-line small cell lung cancer
Editor
-
16 June 2026
0
Phase 3 trials
Eli Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people...
Editor
-
16 June 2026
0
Phase 1-2 trials
Akeso’s next-generation HER3 antibody-drug conjugate AK138D1 combined with ivonescimab: first patient enrolled in phase 1b/2 breast cancer study
Editor
-
16 June 2026
0
Phase 1-2 trials
New MTA-cooperative PRMT5 inhibitor, initiates a phase 1/2 clinical combination study
Editor
-
15 June 2026
0
Phase 3 trials
Izalontamab Brengitecan (Iza-Bren) demonstrates statistically significant and clinically meaningful improvements in overall survival and progression-free survival in patients with triple-negative breast cancer and oesophageal...
Editor
-
15 June 2026
0
Investigational New Drug application
New drug applications for Bayer’s FXIa inhibitor accepted by US Food and Drug Administration under priority review and by Japan’s Ministry of Health, Labour...
Editor
-
9 June 2026
0
Phase 3 trials
New analysis shows Tryngolza (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia
Editor
-
9 June 2026
0
Phase 1-2 trials
BioLineRx and Hemispherian announce new data demonstrating potent anti-tumour effect in Glioblastoma (GBM) across multiple in vivo studies
Editor
-
1 June 2026
0
1
2
3
Page 1 of 3
Most Read
Novartis remibrutinib significantly reduces relapse rates and shows favourable safety profile in phase 3 RMS trials
9 September 2026
GSK to advance mRNA seasonal flu vaccine candidate to phase 3 following positive phase 2 data
9 September 2026
New phase 3b data on Eli Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults...
8 September 2026
Acoramidis demonstrates reversal of cardiac structural disease progression and functional decline and significantly increases days alive and free from hospitalisation in ATTR-CM
8 September 2026
Click to listen highlighted text!